Can Liver Disease Cause Diabetes? (And Vice Versa)

Yes — in both directions. Liver disease can cause diabetes, and diabetes can cause liver disease. The two conditions are so deeply interconnected that having one roughly doubles your risk of developing the other, and having both simultaneously creates a compounding cycle that accelerates damage to both organs faster than either condition would progress alone.

This bidirectional relationship is one of the most clinically significant connections in modern medicine — and one of the least understood by patients. If you have fatty liver and your blood sugar is creeping up, or if you have diabetes and your doctor just mentioned your liver enzymes are elevated, this article explains exactly how the two conditions feed each other, why the combination is so dangerous, and what to do about it.

Direction 1: How liver disease causes diabetes

The liver is your blood sugar control center

Your liver is the organ most responsible for maintaining stable blood glucose. It stores glucose as glycogen after meals (preventing blood sugar spikes) and releases it between meals and overnight (preventing dangerous drops). It produces glucose from non-sugar sources (gluconeogenesis) when needed. It responds to insulin by reducing glucose production — and to glucagon by increasing it. And it clears insulin from the blood — roughly 50% of the insulin your pancreas produces is extracted and broken down by the liver on its first pass.

When liver function deteriorates, every one of these regulatory mechanisms becomes impaired — pushing blood sugar higher and more erratically.

Hepatogenous diabetes: diabetes caused by cirrhosis

Hepatogenous diabetes is diabetes that develops as a direct consequence of cirrhosis — distinct from type 2 diabetes that preceded the liver disease. It affects 30–60% of cirrhosis patients and is driven by several mechanisms simultaneously.

Insulin resistance from portal hypertension: Portal hypertension causes the blood returning from your intestines to bypass the liver through collateral vessels (portosystemic shunts). This means insulin that would normally be extracted by the liver on its first pass instead floods into the systemic circulation at higher-than-normal levels (hyperinsulinemia). Chronically elevated insulin downregulates insulin receptors throughout the body — creating insulin resistance. Your cells stop responding normally to insulin's signal, and blood sugar rises.

Impaired glucose storage: The cirrhotic liver has less functional tissue to store glycogen — so after meals, glucose that should be stored in the liver instead stays in the bloodstream longer, producing higher post-meal blood sugar spikes. Between meals, the depleted glycogen stores run out faster — contributing to the "accelerated starvation" phenomenon that also drives muscle loss.

Inflammatory cytokines: Chronic liver inflammation produces TNF-alpha and IL-6, which directly impair insulin signaling in muscle and fat tissue — creating a systemic insulin-resistant state driven by the liver's inflammatory output.

Altered gut hormones: Liver disease disrupts the gut-liver axis, altering the production and clearance of incretins (GLP-1, GIP) — hormones that help regulate insulin release and blood sugar after meals.

Hepatogenous diabetes carries a unique clinical significance: it independently predicts worse outcomes in cirrhosis — higher rates of HCC, more decompensation events, higher mortality. It's not just an incidental finding. It's a prognostic marker and a management target.

Direction 2: How diabetes causes liver disease

This direction is even more common. Type 2 diabetes is the single strongest metabolic driver of NAFLD and its progression to NASH and cirrhosis.

Insulin resistance drives fat into the liver

In insulin resistance (the hallmark of type 2 diabetes and pre-diabetes), your body's fat metabolism shifts in a direction that overwhelms the liver. Insulin-resistant fat tissue releases excessive free fatty acids into the bloodstream. These fatty acids flood the liver, which absorbs them and converts them to triglycerides — stored as fat droplets inside liver cells. Simultaneously, insulin resistance impairs the liver's ability to export fat (as VLDL) — so fat comes in faster than it goes out. The result: fat accumulates in the liver. This is NAFLD.

Hyperglycemia directly damages the liver

Elevated blood sugar (hyperglycemia) promotes oxidative stress within liver cells, directly damaging cellular structures. It activates inflammatory pathways that drive the transition from simple steatosis to NASH. It promotes advanced glycation end-products (AGEs) that cross-link proteins and stiffen liver tissue. And it stimulates hepatic stellate cell activation — the cellular process that produces fibrosis (scarring). In short, high blood sugar doesn't just put fat in your liver — it sets that fat on fire.

The prevalence tells the story

Studies consistently show that 60–75% of patients with type 2 diabetes have NAFLD. Among those, approximately 20–30% have NASH. And the rate of advanced fibrosis in diabetic NAFLD patients is significantly higher than in non-diabetic NAFLD patients — meaning diabetes accelerates the progression from fat to scarring to cirrhosis.

If you have type 2 diabetes and your liver has never been specifically evaluated (beyond routine enzyme checks), this is a significant gap in your medical care. FibroScan screening for liver fibrosis should be considered for all diabetic patients — and some guidelines are moving toward recommending it.

The vicious cycle: how they accelerate each other

When liver disease and diabetes coexist, they create a self-reinforcing loop that's more destructive than either condition alone:

Insulin resistance → fat accumulates in liver → liver inflammation → more insulin resistance → higher blood sugar → more liver damage → more inflammatory cytokines → worsened insulin resistance → diabetes worsens → liver disease worsens.

Each step feeds the next. Breaking the cycle requires intervening at multiple points simultaneously — not just treating one condition and hoping the other improves on its own.

The clinical consequences of the dual diagnosis include accelerated fibrosis progression (diabetes is the strongest predictor of NAFLD progressing to cirrhosis), higher HCC risk (diabetes independently increases HCC risk, and combined with cirrhosis, the risk compounds), increased cardiovascular risk (the leading cause of death in NAFLD patients — and diabetes amplifies it dramatically), more frequent decompensation events in cirrhosis, worse transplant outcomes (diabetes-related complications increase surgical risk and post-transplant morbidity), and new-onset diabetes after liver transplant (NODAT) in 10–30% of recipients from immunosuppressive medication effects.

How to manage both together

Weight loss: the intervention that treats both

If you are overweight with NAFLD and diabetes (or pre-diabetes), weight loss is the single most effective intervention for both conditions simultaneously. A 7–10% body weight reduction reduces liver fat and inflammation (can reverse early fibrosis), improves insulin sensitivity, lowers HbA1c (a measure of long-term blood sugar control), reduces cardiovascular risk, and may reduce the need for diabetes medications.

The key: lose fat while preserving muscle. High protein intake (1.5–2.0 g/kg ideal body weight for obese cirrhosis patients), regular exercise (aerobic + resistance training), moderate caloric deficit (500–800 kcal/day — never crash diet), and a Mediterranean dietary pattern. Read: Can I Exercise with Cirrhosis?

Blood sugar management

For patients with both liver disease and diabetes, glycemic control directly protects the liver — by reducing the oxidative stress, inflammation, and stellate cell activation that high blood sugar promotes.

Metformin is generally safe in compensated cirrhosis and may have independent liver-protective effects (some studies suggest antifibrotic properties). It should be avoided in decompensated cirrhosis due to lactic acidosis risk. GLP-1 receptor agonists (semaglutide, liraglutide) are particularly promising — they promote weight loss AND have shown direct benefit for NASH in clinical trials. Semaglutide is being studied specifically for NASH treatment. SGLT2 inhibitors (empagliflozin, dapagliflozin) promote weight loss and have cardiovascular benefit. Generally safe in compensated cirrhosis. Pioglitazone (a thiazolidinedione) has the strongest evidence of any diabetes drug for improving NASH histology — reducing inflammation and fibrosis. However, it causes weight gain and fluid retention, which limits its use in patients with ascites. Insulin may be needed in advanced cirrhosis when oral agents are insufficient or contraindicated. Dose requirements often increase as insulin resistance worsens with disease progression.

All diabetes medication decisions in liver disease should involve your hepatologist alongside your endocrinologist or PCP. Dose adjustments and contraindications are liver-stage-specific.

Nutrition: the overlapping priorities

The dietary advice for liver disease and for diabetes overlaps substantially — which simplifies things. Both conditions benefit from Mediterranean diet pattern (olive oil, vegetables, fish, whole grains, legumes, nuts), elimination of added sugar and sugary beverages, high fiber intake, adequate protein (1.2–1.5 g/kg/day for cirrhosis), limited refined carbohydrates, and — for liver patients with ascites — sodium restriction. Use the Food Scanner to check packaged foods for both sodium and sugar content. Explore the Recipe Center for meals that work for both conditions.

Screening: what you need if you have both

If you have diabetes + liver disease, your screening burden is higher — and every element is important. HCC screening (AFP + ultrasound) every 6 months if cirrhosis is present (diabetes increases HCC risk within cirrhosis). FibroScan periodically to assess fibrosis trajectory. HbA1c every 3 months (blood sugar control). Kidney function monitoring (creatinine, GFR) — both diabetes and cirrhosis threaten kidney function. Cardiovascular screening — lipid panels, blood pressure, cardiac evaluation as indicated. Comprehensive eye exam annually (diabetic retinopathy). Foot exams (diabetic neuropathy).

Upload every lab report to LiverTracker. Your liver values, MELD score, and metabolic markers are all tracked on visual trend charts. Share your complete record with both your hepatologist and your endocrinologist — they each need to see the whole picture.

Frequently asked questions

Can curing my liver disease cure my diabetes?

If the diabetes is hepatogenous (caused by cirrhosis), liver transplant often resolves it — confirming the causal relationship. Pre-transplant hepatogenous diabetes resolves in about 50–70% of recipients after successful transplant. If the diabetes is type 2 that preceded liver disease, transplant doesn't cure it — but liver function recovery can improve insulin sensitivity and make diabetes easier to manage. Weight loss that reverses NAFLD can also put type 2 diabetes into remission in some patients.

Does metformin help fatty liver?

Metformin improves insulin sensitivity and helps with weight management — both of which indirectly benefit NAFLD. However, metformin has not been shown to directly improve liver histology (fat content, inflammation, or fibrosis) in clinical trials. It's an excellent diabetes drug that's safe in compensated cirrhosis, but it's not a NAFLD treatment by itself. GLP-1 agonists (semaglutide) and pioglitazone have stronger evidence for direct liver benefit.

I have pre-diabetes and fatty liver. How urgent is this?

More urgent than most people realize. Pre-diabetes is the stage where intervention has the highest impact and the greatest chance of preventing both full diabetes and liver disease progression. A 7% body weight loss at this stage can prevent the conversion to diabetes (Diabetes Prevention Program data) AND reduce liver fat and inflammation. Don't wait for full diabetes to take action — the pre-diabetes window is your best opportunity.

Can I take diabetes medications with cirrhosis?

Yes — but choice and dosing must account for liver function. Metformin is generally safe in compensated cirrhosis (avoid in decompensated). GLP-1 agonists appear safe across stages. SGLT2 inhibitors are safe in compensated disease. Pioglitazone is effective for NASH but causes fluid retention (problematic with ascites). Sulfonylureas should be used cautiously (hypoglycemia risk is higher). Insulin is always an option but doses may need frequent adjustment. Your hepatologist should coordinate with your diabetes provider.

Does diabetes affect my MELD score or transplant eligibility?

Diabetes doesn't directly change your MELD score (which measures bilirubin, INR, creatinine, sodium). However, diabetes-related kidney damage can raise creatinine — which does increase MELD. Regarding transplant eligibility: diabetes is not a contraindication to transplant, but uncontrolled diabetes increases surgical risk. Transplant programs evaluate diabetes management as part of the overall evaluation. Well-controlled diabetes rarely affects candidacy. Poorly controlled diabetes may require optimization before listing.

Your liver and your blood sugar are in a conversation you can't afford to ignore. When one gets worse, the other follows. Treat both. Track both. And understand that the intervention that helps one almost always helps the other.

→ Check Your Liver Enzymes Free

→ Start Tracking Free

→ Take the Liver Health Quiz

Medical Disclaimer: This article is for informational and educational purposes only. Diabetes and liver disease management should be coordinated by your healthcare team. Never change diabetes medications without consulting your doctor. Visit livertracker.com/medical-disclaimer.